Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Creatine in ALS
NCT00005766Phase 2Completed
- Sponsor
- National Center for Research Resources
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Active creatine with Placebo (2 arms). Primary endpoint: Change in upper extremity motor function at 6 months. Status: completed.
02
Drugs
creatine
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT00005766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005766.